RecruitingNCT07205887
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
PHASE2 · 160 planned enrolment
- Countries listed
- 1
- Registry update
- September 4, 2026
immortal.lifeTrial registrations containing the exact intervention label Aflibercept 2.0 mg.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 160 planned enrolment
PHASE4 · 281 planned enrolment